By Application
Hot products 
-
Mouse Anti-AMH Recombinant Antibody (5/6) (CBMAB-A2527-YC)
-
Mouse Anti-GFAP Recombinant Antibody (24) (CBMAB-G2927-LY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
-
Mouse Anti-GFAP Recombinant Antibody (20) (CBMAB-G2914-LY)
-
Mouse Anti-CD24 Recombinant Antibody (ALB9) (CBMAB-0176CQ)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-DLG1 Monolconal Antibody (4F3) (CBMAB-0225-CN)
-
Mouse Anti-ARHGDIA Recombinant Antibody (CBCNA-009) (CBMAB-R0415-CN)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Rabbit Anti-Acetyl-Histone H4 (Lys16) Recombinant Antibody (V2-623415) (CBMAB-CP1021-LY)
-
Mouse Anti-ASH1L Monoclonal Antibody (ASH5H03) (CBMAB-1372-YC)
-
Mouse Anti-EIF4G1 Recombinant Antibody (2A9) (CBMAB-A2544-LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CR3022) (CBMAB-CR014LY)
-
Mouse Anti-GFAP Recombinant Antibody (5) (CBMAB-G0346-LY)
-
Mouse Anti-ADIPOR2 Recombinant Antibody (V2-179983) (CBMAB-A1369-YC)
-
Mouse Anti-DMPK Recombinant Antibody (CBYCD-324) (CBMAB-D1200-YC)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
Loading...
Compare
